Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-12 3:54 pm Purchase |
2024-12-31 | 13G | TELA Bio, Inc. TELA |
SILVERARC CAPITAL MANAGEMENT LLC | 3,065,649 7.800% |
3,065,649 (New Position) |
Filing History |
| 2025-02-12 3:53 pm Sale |
2024-12-31 | 13G | Molecular Templates, Inc. MTEM |
SILVERARC CAPITAL MANAGEMENT LLC | 0 0.000% |
-354,608 (Position Closed) |
Filing History |
| 2025-02-12 3:44 pm Purchase |
2024-12-31 | 13G | Elutia Inc. ELUT |
SILVERARC CAPITAL MANAGEMENT LLC | 1,782,271 5.900% |
136,463 (+8.29%) |
Filing History |
| 2024-10-15 06:59 am Purchase |
2024-10-11 | 13G | Elutia Inc. ELUT |
SILVERARC CAPITAL MANAGEMENT LLC | 1,645,808 5.530% |
1,645,808 (New Position) |
Filing History |
| 2024-10-15 06:55 am Sale |
2024-10-11 | 13G | Mersana Therapeutics, Inc. MRSN |
SILVERARC CAPITAL MANAGEMENT LLC | 1,754,086 1.430% |
-4,666,050 (-72.68%) |
Filing History |
| 2024-10-15 06:52 am Sale |
2024-10-11 | 13G | Evogene Ltd. EVGN |
SILVERARC CAPITAL MANAGEMENT LLC | 307,972 3.520% |
-2,028 (-0.65%) |
Filing History |
| 2024-02-14 8:43 pm Purchase |
2023-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
SILVERARC CAPITAL MANAGEMENT LLC | 6,420,136 5.300% |
6,420,136 (New Position) |
Filing History |
| 2024-02-14 8:39 pm Purchase |
2023-12-31 | 13G | Molecular Templates, Inc. MTEM |
SILVERARC CAPITAL MANAGEMENT LLC | 354,608 6.600% |
354,608 (New Position) |
Filing History |
| 2024-02-14 8:30 pm Purchase |
2023-12-31 | 13G | Evogene Ltd. EVGN |
SILVERARC CAPITAL MANAGEMENT LLC | 310,000 6.100% |
310,000 (New Position) |
Filing History |
| 2023-02-07 5:38 pm Sale |
2022-12-31 | 13G | Benitec Biopharma Inc. BNTC |
SILVERARC CAPITAL MANAGEMENT LLC | 0 0.000% |
-34,559 (Position Closed) |
Filing History |
| 2022-02-10 09:09 am Unchanged |
2021-12-31 | 13G | Benitec Biopharma Inc. BNTC |
SILVERARC CAPITAL MANAGEMENT LLC | 34,559 7.200% |
0 (Unchanged) |
Filing History |
| 2022-02-10 09:07 am Unchanged |
2021-12-31 | 13G | Benitec Biopharma Inc. BNTC |
SILVERARC CAPITAL MANAGEMENT LLC | 34,559 7.200% |
0 (Unchanged) |
Filing History |
| 2022-02-09 4:39 pm Purchase |
2021-12-31 | 13G | Benitec Biopharma Inc. BNTC |
SILVERARC CAPITAL MANAGEMENT LLC | 34,559 7.200% |
34,559 (New Position) |
Filing History |
| 2022-02-08 4:48 pm Sale |
2021-12-31 | 13G | Delcath Systems, Inc. DCTH |
SILVERARC CAPITAL MANAGEMENT LLC | 0 0.000% |
-351,616 (Position Closed) |
Filing History |
| 2021-03-10 11:19 am Purchase |
2020-12-31 | 13G | Delcath Systems, Inc. DCTH |
SILVERARC CAPITAL MANAGEMENT LLC | 351,616 5.900% |
351,616 (New Position) |
Filing History |